Medigene has appointed Prof. Dr Dolores J. Schendel to the Executive Board as Chief Scientific Officer

Medigene AG / Medigene has appointed Prof. Dr Dolores J. Schendel to the Executive Board as Chief Scientific Officer . Processed and transmitted by Nasdaq OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Martinsried/Munich, 30 April 2014. Biotech company Medigene AG (Frankfurt: MDG1, Prime Standard) is pleased to announce that the company's Supervisory Board has as planned appointed Prof. Dr. Dolores J. Schendel as Chief Scientific Officer of Medigene AG  effective 1 May 2014. Former Director of the Institute of Molecular Immunology at the Helmholtz-Zentrum München and Managing Director of Trianta Immunotherapies GmbH, Prof. Schendel will now be the Executive Board member responsible for research and development at Medigene. She will continue as Member of the Management Board of Trianta Immunotherapies GmbH, which was acquired by Medigene in January 2014. With the appointment of Prof. Schendel, the Executive Board of Medigene AG has increased to three members.

Prof. Dr. Horst Domdey, Chairman of the Supervisory Board of Medigene AG, comments: "We are proud to have an exceptional immunologist and experienced manager such as Prof. Dolores Schendel joining the Executive Board of Medigene. Her internationally recognised scientific expertise and management skills, as well as the highly innovative immunotherapy technologies she has developed with her team, will add significant value to Medigene AG."

Prof. Dr. Dolores Schendel, Executive Board member responsible for research and development at Medigene AG from 1 May 2014: "I am very much looking forward to working together with the experienced Medigene team on the continued development of technologies and drug candidates, which could help improve the lives of seriously ill patients in future. The close collaboration with Medigene has been very positive so far, both from a personal and a professional standpoint. I am certain that the merger and integration of the two companies, Medigene and Trianta, which has almost been successfully concluded, offers great potential for the future."

About Prof. Dolores J. Schendel: Prof. Dolores J. Schendel, Managing Director of Trianta Immunotherapies GmbH, has been Director of the Institute of Molecular Immunology of the German Research Center for Environmental Health since 1998 and has held an adjunct professorship in immunology at the Ludwig Maximilian University of Munich since 1986. Her research focuses on human immunology and immunotherapy. She has led preclinical groups for GMP process development and immune monitoring for clinical studies. Prof. Schendel has experience in building and guiding diverse teams required to initiate clinical studies of new immunotherapy strategies based on DC vaccines and adoptive T cell therapy. She has served as a Member of the German Cancer Aid Grants Review Panel and as Chair of a Life Science Study Panel of the European Research Council.

About Trianta: Trianta Immunotherapies GmbH, a wholly owned subsidiary of Medigene AG, is at the forefront of personalized T cell immunotherapy, focussing on next generation antigen-tailored dendritic cell (DC) vaccines, T cell receptor (TCR)-based adoptive cell therapy and T cell-targeted antibodies (TABs). Trianta Immunotherapies was founded late 2013 as a spin-off of the Helmholtz Zentrum München, the German Research Centre for Environmental Health. Trianta exploits the therapeutic and commercial potential of T cell-focused therapies developed by the team of Prof. Dolores J. Schendel at the Helmholtz Zentrum Munich, in collaboration with Prof. Thomas Blankenstein at the Max Delbrück Centre for Molecular Medicine, Berlin. The team of Trianta pursues three complementary immunotherapeutic strategies to target various tumour types and stages. Each one is focused on T cells, a type of white blood cell that plays a pivotal role in immunity. Trianta Immunotherapies was acquired by Medigene in January 2014.

Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. Medigene concentrates on the development of personalized T cell immunotherapies with focus on haematological malignancies. Medigene is the first German biotech company to have revenues from a marketed product, Veregen®, which is distributed by commercial partners companies. Medigene has various drug candidates in clinical development and it is developing highly innovative treatment platforms. For more information, please visit www.medigene.com.

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® EndoTAG® and Veregen®are registered trademarks of Medigene AG. Polyphenon E® is a trademark of Mitsui Norin Co., Ltd. These trademarks may be owned or licensed in select locations only.

Contact
Julia Hofmann, Claudia Burmester
Tel.: +49 - 89 - 20 00 33 - 33 01
Email: investor@medigene.com

To unsubscribe from the press release distribution list, please go to: http://www.medigene.de/unsubscribe

--- End of Message ---

Medigene AG
Lochhamer Strasse 11 Martinsried / München Germany

WKN: A1X3W0;ISIN: DE000A1X3W00;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;